知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

1918 条记录 (耗时 0.032 秒)

    USES OF PATIENT-DERIVED SCAFFOLDS
    32.
    发明公开
    USES OF PATIENT-DERIVED SCAFFOLDS 审中-公开

    公开(公告)号：US20230407267A1

    公开(公告)日：2023-12-21

    申请号：US18251326

    申请日：2021-10-26

    申请人： Iscaff Pharma AB

    发明人： Göran Landberg ,  Anders Ståhlberg

    IPC分类号： C12N5/09

    CPC分类号： C12N5/0693 ,  C12N2503/04 ,  C12N2533/90

    摘要： Cell-free scaffolds derived from tumors in patients are used as in vitro cancer models and also provide information of the tumor, from which it is derived, including its susceptibility to cancer treatment. The cell-free scaffolds are also used as a predictive tool in assessing cancer treatment efficacy and in identifying immunotargets and biomarkers for cancer therapy.

    HUMAN PRIMARY MYELOFIBROSIS CELL STRAIN AND USE THEREOF
    35.
    发明公开
    HUMAN PRIMARY MYELOFIBROSIS CELL STRAIN AND USE THEREOF 审中-公开

    公开(公告)号：US20230357726A1

    公开(公告)日：2023-11-09

    申请号：US18336001

    申请日：2023-06-15

    申请人： ZHEJIANG UNIVERSITY

    发明人： Jie JIN ,  Fenglin LI ,  Yile ZHOU ,  Wenjuan YU ,  Jinghan WANG ,  Xin HUANG ,  Yungui WANG

    IPC分类号： C12N5/09 ,  G01N33/50

    CPC分类号： C12N5/0694 ,  G01N33/5011

    摘要： Providing a human primary myelofibrosis (PMF) cell strain, a construction method therefor and use thereof. The PMF cell strain is named as ZYXY-M2, and is deposited in China Center for Type Culture Collection (Wuhan University, Wuhan, China), with a preservation number of CCTCC NO: C202145. The present application is obtained by extracting and separating mononuclear cells from peripheral blood of a PMF patient and culturing in vitro for continuous natural passage. The leukemia cell strain is negative for JAK2, CALR, MPL mutation, positive for ASXL1, TP53, IKZF1, IDH1, FLT3 and TET1. The cell strain has good proliferation ability in vitro, and can be used as a cell material to study the pathogenesis of PMF and individualized treatment in vitro. Meanwhile, it can also be used to screen and evaluate drugs for in vitro and in vivo research of human PMF and guide clinical medication.

    METHODS AND VACCINE COMPOSITIONS TO TREAT CANCERS
    36.
    发明公开
    METHODS AND VACCINE COMPOSITIONS TO TREAT CANCERS 审中-公开

    公开(公告)号：US20230346901A1

    公开(公告)日：2023-11-02

    申请号：US17786908

    申请日：2020-12-18

    申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ PARIS CITÉ

    发明人： Jean-Luc POYET ,  Justine HABAULT ,  Marie PLA

    IPC分类号： A61K39/00 ,  A61P35/02 ,  A61P35/00 ,  C12N5/09

    CPC分类号： A61K39/0011 ,  A61P35/02 ,  A61P35/00 ,  C12N5/0694 ,  A61K2039/5152 ,  A61K2039/55 ,  C12N2501/06

    摘要： The present invention relates to a method for obtaining a population of oncogenic cells modified comprising the following steps: i) obtaining a population of oncogenic cells from a subject suffering from a cancer; and ii) treating said cells with a fusion protein comprising an AAC-11 leucine-zipper (LZ) derived peptide which is fused to at least one heterologous polypeptide. Inventors have evaluated here the antileukemic efficacy of RT53, an anticancer peptide with potential immunological properties. Their results indicate that RT53 possesses a direct antileukemic effect, even at late stage. They also demonstrated that single injection of a vaccine consisting of leukemic blasts exposed to RT53, which induces the hallmarks of immunogenic cell death, was highly effective in preventing leukemia development in both prophylactic and therapeutic settings. The vaccine comprising RT53-treated APL cells generated long-term antileukemic protection and depletion experiments indicated that CD4+ T cells were of crucial importance for vaccine efficacy. Combined, their results provide the rational for the exploration of RT53-based therapies for the treatment of cancer, such as acute leukemia.

    COLD PLASMA TREATMENT MEDIATED MUTANT SPECIFIC T CELL IMMUNITY
    38.
    发明公开
    COLD PLASMA TREATMENT MEDIATED MUTANT SPECIFIC T CELL IMMUNITY 审中-公开

    公开(公告)号：US20230313147A1

    公开(公告)日：2023-10-05

    申请号：US18207487

    申请日：2023-06-08

    申请人： Jerome Canady Research Institute for Advanced Biological and Technological Sciences

    发明人： Jerome Canady ,  Saravana Murthy ,  Xiaoqian Cheng ,  Taisen Zhuang

    IPC分类号： C12N5/09

    CPC分类号： C12N5/0693 ,  C12N2500/02

    摘要： A method for producing cold atmospheric plasma-produced exosomes ex vivo for use in systemic treatment of cancer. The method comprises isolating patient cancerous tumor primary cells, culturing isolated patient cancerous tumor primary cells in appropriate culture media, sequencing said isolated patient cancerous tumor primary cells and identifying mutant genes, transfecting mutant genes into pots of cells, wherein the transformed cells overexpress a unique mutant protein, treating the pots of transformed cells with cold atmospheric plasma to cause apoptosis of said transformed cells, wherein apoptotic cells secrete exosomes containing oxidized mutant proteins, isolating said exosomes containing oxidized mutant proteins, and storing said exosomes. The method may further comprise injecting said exosomes into a patient to systemically treat cancer.